Show simple item record

dc.contributor.authorCharle-Cuellar, Pilar 
dc.contributor.authorBerzosa, Pedro 
dc.contributor.authorLucio, Aida de 
dc.contributor.authorRaso, José
dc.contributor.authorNseng Nchama, Gloria
dc.contributor.authorBenito, Agustin
dc.identifier.citationAm J Trop Med Hyg. 2013;88(6):1087-92.es_ES
dc.description.abstractThe objectives of this study were: 1) to evaluate the safety and efficacy of combination artesunate (AS)/amodiaquine (AQ) therapy, and 2) to determine the difference between recrudescence and resistance. An in vivo efficacy study was conducted in Equatorial Guinea. A total of 122 children 6-59 months of age from two regional hospitals were randomized and subjected to a 28-day clinical and parasitological follow-up. A blood sample on Whatman paper was taken on Days 0, 7, 14, 21, and 28 or on any day in cases of treatment failure, with the parasite DNA then being extracted for molecular analysis purposes. A total of 4 children were excluded, and 9 cases were lost to follow-up. There were 17 cases of late parasitological failure, 3 cases of late clinical failure, and 89 cases of adequate clinical and parasitological response. The parasitological failure rate was 18.3% (20 of 109) and the success rate 81.70% (95% confidence interval [72.5-87.9%]). After molecular correction, real treatment efficacy stood at 97.3%. Our study showed the good efficacy of combination AS/AQ therapy. This finding enabled this treatment to be recommended to Equatorial Guinea's National Malaria Control Program to change the official treatment policy as of March 2008.es_ES
dc.description.sponsorshipThis study received financial support from Spain’s International Development Aid Agency (Agencia Espanñola de Cooperación Internacional para el Desarrollo - AECID) and the National Centre of Tropical Medicine at the Carlos III Institute of Health. Cooperative Research in Tropical Diseases (CRTD), Project: RD06/0021/0000.es_ES
dc.publisherAmerican Society of Tropical Medicine and Hygiene (ASTMH) es_ES
dc.subject.meshAmodiaquine es_ES
dc.subject.meshArtemisinins es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshDNA, Protozoan es_ES
dc.subject.meshDrug Combinations es_ES
dc.subject.meshEquatorial Guinea es_ES
dc.subject.meshFemale es_ES
dc.subject.meshFollow-Up Studies es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfant es_ES
dc.subject.meshMalaria, Falciparum es_ES
dc.subject.meshMale es_ES
dc.subject.meshPlasmodium falciparum es_ES
dc.subject.meshPyrimethamine es_ES
dc.subject.meshSulfadoxine es_ES
dc.subject.meshTreatment Failure es_ES
dc.subject.meshWorld Health Organization es_ES
dc.titleArtesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa)es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderAgencia Española de Cooperación Internacional para el Desarrollo 
dc.contributor.funderInstituto de Salud Carlos III 
dc.identifier.journalThe American journal of tropical medicine and hygienees_ES
dc.repisalud.centroISCIII::Centro Nacional de Medicina Tropicales_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional